Kronos Bio, Inc.2024财年第三财季实现净利润-14.11百万美元，同比增加55.02%

市场透视11-23

11月23日，Kronos Bio, Inc.（KRON.US）公布财报，公告显示公司2024财年第三财季净利润为-14.11百万美元，同比增加55.02%；其中营业收入为2.37百万美元，同比增加158.45%，每股基本收益为-0.23美元。从资产负债表来看，Kronos Bio, Inc.（KRON.US）总负债38.90百万美元，其中短期债务3.26百万美元，资产负债比为0.04，流动比率为...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2485298753?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-23 00:01","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2485298753","market":"us","top_or_hot":-1,"title":"Kronos Bio, Inc.2024财年第三财季实现净利润-14.11百万美元，同比增加55.02%","media":"市场透视","content":"<div>\n<p>11月23日，Kronos Bio, Inc.（KRON.US）公布财报，公告显示公司2024财年第三财季净利润为-14.11百万美元，同比增加55.02%；其中营业收入为2.37百万美元，同比增加158.45%，每股基本收益为-0.23美元。从资产负债表来看，Kronos Bio, Inc.（KRON.US）总负债38.90百万美元，其中短期债务3.26百万美元，资产负债比为0.04，流动比率为...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241123000139abd7b870&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kronos Bio, Inc.2024财年第三财季实现净利润-14.11百万美元，同比增加55.02%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKronos Bio, Inc.2024财年第三财季实现净利润-14.11百万美元，同比增加55.02%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-23 00:01 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241123000139abd7b870&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>11月23日，Kronos Bio, Inc.（KRON.US）公布财报，公告显示公司2024财年第三财季净利润为-14.11百万美元，同比增加55.02%；其中营业收入为2.37百万美元，同比增加158.45%，每股基本收益为-0.23美元。从资产负债表来看，Kronos Bio, Inc.（KRON.US）总负债38.90百万美元，其中短期债务3.26百万美元，资产负债比为0.04，流动比率为...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241123000139abd7b870&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KRON","symbol_name":"Kronos Bio, Inc.","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241123000139abd7b870&s=b","article_id":"2485298753","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241123000139abd7b870&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2485298753","pubTimestamp":1732291274,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"11月23日，Kronos Bio, Inc.公布财报，公告显示公司2024财年第三财季净利润为-14.11百万美元，同比增加55.02%；其中营业收入为2.37百万美元，同比增加158.45%，每股基本收益为-0.23美元。从资产负债表来看，Kronos Bio, Inc.总负债38.90百万美元，其中短期债务3.26百万美元，资产负债比为0.04，流动比率为0.09。机构评级：截至2024年11月23日，当前有2家机构对Kronos Bio, Inc.目标价做出预测，其中目标均价为1.62美元，其中最低目标价为1.00美元，最高目标价为2.25美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"KRON":"Kronos Bio, Inc."},"translate_title":"Kronos Bio, Inc. achieved net profit of-US $14.11 million in the third fiscal quarter of fiscal year 2024, a year-on-year increase of 55.02%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KRON":1},"content_text":"11月23日，Kronos Bio, Inc.（KRON.US）公布财报，公告显示公司2024财年第三财季净利润为-14.11百万美元，同比增加55.02%；其中营业收入为2.37百万美元，同比增加158.45%，每股基本收益为-0.23美元。从资产负债表来看，Kronos Bio, Inc.（KRON.US）总负债38.90百万美元，其中短期债务3.26百万美元，资产负债比为0.04，流动比率为0.09。机构评级：截至2024年11月23日，当前有2家机构对Kronos Bio, Inc.目标价做出预测，其中目标均价为1.62美元，其中最低目标价为1.00美元，最高目标价为2.25美元。公司简介：Kronos Bio Inc 是一家专注于发现和开发新型癌症治疗药物的临床阶段生物制药公司，旨在通过精准医学方案，通过靶向失调的转录来改变患者预后。该公司在一个业务部门运营，即生物制药产品的开发。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2485298753"}